Antibodies increase 6-20 times after second dose of Pfizer – Sheba

The amount of antibodies produced to defend against the new coronavirus has increased six-fold to 12-fold for people who received their second dose of the Pfizer vaccine, Tel Hashomer Sheba Medical Center reported on Monday. cases of medical personnel vaccinated in hospital. They had more antibodies than those severely infected with the virus and recovered. “The results of the investigation are in line with Pfizer’s experience and even better than expected,” Professor Gili Regev-Yochay, director of Sheba’s infectious disease epidemiology unit, said in a briefing Monday. “I expect the results of the survey of other participating employees to be similar. There are certainly reasons to be optimistic. The upshot of the data is that Israel is expected to see a reduction in the coronavirus outbreak across the country as more people receive their second dose, she said. is immunocompromised, said Regev-Yochay. There was no explanation as to why the second person did not develop antibodies, and the hospital is investigating the matter, she said. Of these, 4,484 received their second dose on Monday. Although the study only looked at 102 cases, more were being evaluated, Regev-Yochay said. The study looks specifically at immunoglobulin G (IgG) antibodies, which determine whether a patient has developed immunity. The study does not say how long the immunity will last or whether a person who has antibodies can still carry the virus and infect others, Regev-Yochay said. However, she said it seemed to her that people who were vaccinated would not spread the virus, meaning they would not pass it on to others.

While sick and recovered people are not yet eligible to receive the Pfizer vaccine in Israel, if further research shows that the vaccine improves immunity, it is possible that they will be inoculated in a second phase, at least with the reminder, says Regev-Yochay.